ProCE Banner Activity

Treatment Options for the Most Common Targetable Biomarkers for Advanced NSCLC: EGFR and KRAS

Slideset Download
Download these slides from a live webinar for a review of recent data on treatment selection for patients with EGFR- or KRAS-positive NSCLC.

Released: April 11, 2022

Expiration: April 10, 2023

Share

Faculty

Joshua K. Sabari

Joshua K. Sabari, MD

Assistant Professor of Medicine
Thoracic Medical Oncology
NYU Langone Health
Perlmutter Cancer Center
NYU Grossman School of Medicine
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Lilly

Novartis Pharmaceuticals Corporation

Turning Point Therapeutics Inc

Faculty Disclosure

Primary Author

Joshua K. Sabari, MD

Assistant Professor of Medicine
Thoracic Medical Oncology
NYU Langone Health
Perlmutter Cancer Center
NYU Grossman School of Medicine
New York, New York